Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 5,241 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Germ Cell Tumor Clear all

Conditions: Cancer
Interventions: floxuridine, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Gliosarcoma, Supratentorial Glioblastoma
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Temozolomide; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 390
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more

Conditions: Brain Tumor, Medulloblastoma
Interventions: [18F]DPA714; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years to 39 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Glioblastoma
Interventions: Aminolevulinic Acid; Drug
Lead sponsor: Matthew R Quigley; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Melanoma
Interventions: Trametinib (GSK1120212), GSK2141795; Drug
Lead sponsor: Adil Daud; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain
Interventions: Fluciclovine F18; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma (Skin), Metastatic Cancer
Interventions: imiquimod, indocyanine green solution, flow cytometry, immunologic technique, laboratory biomarker analysis; Drug · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Glioblastoma, Gliomas
Interventions: Temozolomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Cancer
Interventions: eFT508; Drug
Lead sponsor: Effector Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more

Conditions: Malignant Melanoma
Interventions: gp75 DNA vaccine; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Melanoma
Interventions: EuroQoL EQ-5D-3L, EORTC QLQ-C30, PRO-CTCAE, Fatigue severity score questionnaire, The COST, Physician information; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Melanoma
Interventions: Dabrafenib, Trametinib, Placebos; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more

Conditions: Glioblastoma Multiforme
Interventions: Not listed
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Meningeal Hemangiopericytoma, Adult Papillary Meningioma, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Recurrent Adult Brain Tumor
Interventions: bevacizumab; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 2 more

Conditions: Malignant Glioma
Interventions: Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 111
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more

Conditions: Melanoma (Skin)
Interventions: paclitaxel albumin-stabilized nanoparticle formulation; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
Interventions: Paltusotine, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 17
States / cities: Gilbert, Arizona • Newport Beach, California • New Haven, Connecticut + 14 more

Conditions: Glioblastoma (GBM)
Interventions: MT-125; Drug
Lead sponsor: Myosin Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Melanoma (Skin)
Interventions: Shade + app with messaging, Shape + app without messaging; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer, Melanoma
Interventions: Lymphoseek; Drug
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 4 more

Conditions: Uveal Melanoma
Interventions: ADI PEG20, Nivolumab, Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors
Interventions: Pamiparib, TMZ, Radiation; Drug · Radiation
Lead sponsor: BeiGene USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 18
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more

Conditions: Adult Solid Neoplasm, Childhood Solid Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Malignant Solid Neoplasm, Refractory Central Nervous System Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib, Temozolomide; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 13 Months to 30 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more

Search by objective public record fields.

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study

Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Study of gp75 Vaccine in Patients With Stage III and IV Melanoma

Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

MRI Predictors of Response to Tumor Treating Fields

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies